Improving Cancer Clinical Trial Participation ... - CLL Support

CLL Support

22,532 members38,709 posts

Improving Cancer Clinical Trial Participation and Eligibility Criteria - Julia Beaver, MD, US Food and Drug Administration (FDA)

AussieNeil profile image
AussieNeilAdministrator
1 Reply

Cancer Network: How big of a problem is accrual of participants in clinical cancer treatment trials?

Dr. Beaver: Cancer trials are known to have very low accrual rates; it has been estimated that fewer than 3% of patients with cancer participate in a clinical trial. Reasons for low clinical trial accrual rates stem from patient-level, physician-level, institutional-level, and protocol-level barriers.

Full interview: cancernetwork.com/asco-stre...

Neil

Written by
AussieNeil profile image
AussieNeil
Administrator
To view profiles and participate in discussions please or .
Read more about...
1 Reply
cllady01 profile image
cllady01Former Volunteer

Interesting, but concerning. The interview brought up for me the reality of aging and comorbidities---coupled with the trials excluding the very age group most likely to have comorbidities, AND, the fact that some of the drugs developed trigger the very problems that aging brings on. A conundrum to be sure.

You may also like...

Mode of Progression After Frontline Treatment Predicts Clinical Outcomes in Patients With CLL

their patients and researchers in designing future clinical trials.” The clinical trials...

Clinical trial with monoclonal antibodies?

I've been asked to participate in a clinical trial in which I get an infusion of monoclonal...

A new kid on the block? Nemtabrutinib

“First in human trial of new drug raises hopes for patients with relapsed blood cancer” dated...

An Early Look at When CAR-T Therapy Fails Patients With CLL

characteristics of patients with CLL who received anti-CD19 CAR-T therapy during a clinical trial...

Progression Free Survival (PFS) post Discontinuation of Ibrutinib in E1912 Trial

An update re the E1912 trial reported at iwCLL this year - \\"patients who stopped ibrutinib for...